Antitumor effects of polyclonal antithymocyte globulins: Focus on B-cell malignancies and multiple myeloma

Annals of Hematology

Volumn 88, Issue 5, 2009, Pages 401-404

  Ayuk, Francis ^a   Zander, Axel ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antitumor; ATG; Hematological malignancies

Indexed keywords

ALEMTUZUMAB; ATG FRESENIUS; FLUDARABINE; MELPHALAN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LEUKEMIA; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; DRUG POTENTIATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HUMAN; IN VITRO STUDY; LYMPH NODE IRRADIATION; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RECOMMENDED DRUG DOSE; REVIEW; T CELL LEUKEMIA; T LYMPHOCYTE; B CELL LYMPHOMA; BLOOD DISEASE;

ANTILYMPHOCYTE SERUM; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; MULTIPLE MYELOMA;

EID: 63649135300     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0696-8     Document Type: Review

References (40)

1. Zander AR, Zabelina T, Kröger N et al (1999) Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 23:889-893
2. Finke J, Bertz H, Schmoor C et al (2000) Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T cell globulin. Br J Haematol 111:303-313
3. Remberger M, Svahn B-M, Hentschke P et al (1991) Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 24:823-830
4. Bacigalupo A, Lamparelli T, Bruzzi P et al (2001) Antithymocyte globulin for graft-versus-host disease prophylaxes in transplants form unrelated donor: 2 randomized studies from Gruppo Italiono Trapianti Midollo Osseo (GITMO). Blood 98:2942-2947
5. Meijer E, Cornelissen JJ, Lowenberg B, Verdonck LF (2003) Antithymocyteglobulin as prophylaxis of graft-versus-host disease in recipients of partially depleted grafts from matched unrelated donors: A dose finding study. Exp Hematol 31:1026-1030
6. Kalwak K, Moson I, Cwian J et al (2003) A prospective analysis of immune recovery in children following allogeneic transplantation of t-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors. Transplant Proc 35:1551-1555
7. Meijer E, Bloem AC, Dekker AW, Verdonk LF (2003) Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell depleted bone marrow transplantation: A comparison of matched related and matched unrelated grafts. Transplantation 75:1910-1913
8. Fehse N, Fehse B, Kroger N et al (2003) Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. J Hematother Stem Cell Res 12:237-242
9. Kröger N, Shaw B, Iacobelli S et al (2005) The Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 129(5):631-643
10. Ayuk F, Perez-Simon A, Shimoni A et al (2008) Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica 93(9):1343-1350, Sep
11. Bonnefoy-Berard N, Genestier L, Flacher M et al (1994) Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. Blood 83:1051-1059
12. Zand MS, Vo T, Huggins J et al (2005) Polyclonal rabbit antithymocyte globulin triggers B-cell apoptosis by multiple pathways. Transplantation 79:1507-1515
13. Ayuk F, Fang L, Fehse B et al (2005) Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. Exp Hematol 33:1531-1536
14. Bonnefoy-Berard N, Revillard JP (1996) Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 15(5):435-442
15. Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP (2003) Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 75:657-662
16. Bonnefoy-Berard N, Vincent C, Revillard JP (1991) Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 51:669-673
17. Raefsky EL, Gascon P, Gratwohl A, Speck B, Young NS (1986) Biological and immunological characterization of ATG and ALG. Blood 68:712-719
18. Rebellato LM, Gross U, Verbanac KM, Thomas JM (1994) A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulins. Transplantation 57:685-694
19. Preville X, Nicolas L, Flacher M, Revillard J (2000) A quantitative flow cytometry assay for the preclinical testing and pharmacological monitoring of rabbit antilymphocyte globulin (rATG). J Immunol Methods 245:45-54
20. Pistillo MP, Tazzari PL, Bonifazi F et al (2002) Detection of a novel specificity (CTLA-4) in ATG/TMG Globulins and sera from ATG-treated leukemic patients. Transplantation 73:1295-1302
21. Bourdage JS, Hamlin DM (1995) Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 27:1194-1200
22. Bacigalupo A, Lamparelli T, Bruzzi P et al (2001) Antithymocyte globulin for graft-versus-host disease prophylaxes in transplants form unrelated donor: 2 randomized studies from Gruppo Italiono Trapianti Midollo Osseo (GITMO). Blood 98:2942-2947
23. Meijer E, Cornelissen JJ, Lowenberg B, Verdonck LF (2003) Antithymocyteglobulin as prophylaxis of graft-versus-host disease in recipients of partially depleted grafts from matched unrelated donors: A dose finding study. Exp Hematol 31:1026-1030
24. Duggan P, Booth K, Chaudhry A et al (2002) Alberta Blood and Bone Marrow Transplant Program. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: A matched pair analysis. Bone Marrow Transplant 30:681-686
25. Schleuning M, Gunther W, Tischer J et al (2003) Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML. Bone Marrow Transplant 32:243-250
26. Zander AR, Zabelina T, Kröger N et al (1999) Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant. 23:889-893
27. Eiermann TH, Lambrecht P, Zander AR (1999) Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 23:779-781
28. Yoshimi A, Ito M, Kojima S (2005) Leukemic cell death induced by antithymocyte globulin. Leuk Res 29:821-827
29. Bonnefoy-Berard N, Flacher M, Revillard JP (1992) Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. Blood 79(8):2164-2170, Apr 15
30. Ayuk F, Atassi N, Schuch G et al (2008) Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. Leuk Res. 32(8):1200-1206, Aug
31. Singal R, Winfield DA, Greaves M (1991) Bone marrow aplasia in B cell chronic lymphocytic leukaemia: Successful treatment with antithymocyte globulin. J Clin Pathol 44:954-956
32. Radosevich CA, Gordon LI, Weil SC, Marder RJ, Rosen ST (1988) Complete resolution of pure red cell aplasia in a patient with chronic lymphocytic leukemia following antithymocyte globulin therapy. JAMA 5:723-725
33. Lowsky R, Takahashi T, Liu YP et al (2005) Protective conditioning for acute graft-versus-host disease. N Engl J Med 353(13):1321-1331
34. Zand MS, Vo T, Pellogrin T et al (2006) Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 107:2895-2903
35. Timm MM, Kimlinger TK, Haug JL et al (2006) Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. Leukemia 20:1863-1869
36. Kröger N, Perez-Simon JA, Myint H et al (2004) Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 10:698-708
37. Perez-Simon JA, Martino R, Alegre A et al (2003) Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Hematol 121:104-108
38. Treon SP, Pilarski LM, Belch AR et al (2002) CD20-directed serotherapy in patients with multiple myeloma: Biological considerations and the therapeutic applications. J Immunother 25:72-81
39. Tai YT, Catley LP, Mitsiades CS et al (2004) Mechanisms by which SGN-40, a humanized anti-CD40 antibody induces cytotoxicity in human multiple myeloma cells: Clinical implications. Cancer Res 64:2846-2852
40. Matsui W, Huff CA, Wang Q et al (2004) Characterization of clonogenic multiple myeloma cells. Blood 103:2332-2336